Yannik Régimbald Dumas
About Yannik Régimbald Dumas
Yannik Régimbald Dumas serves as Principal Scientist and Group Leader at Jnana Therapeutics, where he focuses on the therapeutic potential of SLCs. He holds a PhD in Health Sciences from Université de Sherbrooke and has extensive experience in biochemistry and molecular biology from his time at Harvard Medical School.
Work at Jnana Therapeutics
Yannik Régimbald Dumas serves as Principal Scientist and Group Leader at Jnana Therapeutics, a position he has held since 2021. His work focuses on the potential of SLCs (Solute Carriers) as therapeutic targets. Dumas emphasizes the sense of fellowship and mission he has found within the organization, describing his experience as a journey that is both humbling and impactful.
Education and Expertise
Yannik Régimbald Dumas has an extensive educational background in health sciences and biotechnology. He studied at the Université de Sherbrooke, where he earned a Doctor of Philosophy (PhD) from 2004 to 2010, focusing on pharmacology. Prior to that, he completed a degree in Biotechnology at the same institution from 2000 to 2004. Additionally, he pursued advanced studies in Biochemistry and Molecular Biology as a Research Fellow at Harvard Medical School from 2011 to 2019.
Background
Dumas began his academic journey at the Université de Sherbrooke, where he engaged in studies related to health sciences and pharmacology. He transitioned to Harvard Medical School, where he furthered his research in biochemistry and molecular biology. His professional career includes significant research roles, notably as a Research Fellow at Harvard Medical School for eight years, before joining Jnana Therapeutics.
Professional Experience
Before his current role at Jnana Therapeutics, Yannik Régimbald Dumas worked at Harvard Medical School as a Research Fellow from 2011 to 2019. His experience there contributed to his expertise in biochemistry and molecular biology. Dumas also held a position at Université de Sherbrooke as a Ph.D. student in pharmacology from 2004 to 2010, where he developed foundational knowledge in the field.